SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-13-044329
Filing Date
2013-08-09
Accepted
2013-08-09 14:40:41
Documents
11
Period of Report
2013-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v352406_10q.htm 10-Q 396805
2 EXHIBIT 31.1 v352406_ex31-1.htm EX-31.1 7940
3 EXHIBIT 31.2 v352406_ex31-2.htm EX-31.2 7931
4 EXHIBIT 32.1 v352406_ex32-1.htm EX-32.1 3728
5 EXHIBIT 32.2 v352406_ex32-2.htm EX-32.2 3768
  Complete submission text file 0001144204-13-044329.txt   4902384

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20130630.xml EX-101.INS 337652
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20130630.xsd EX-101.SCH 31482
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20130630_cal.xml EX-101.CAL 44497
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20130630_def.xml EX-101.DEF 92985
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20130630_lab.xml EX-101.LAB 311531
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20130630_pre.xml EX-101.PRE 220142
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 131025979
SIC: 2835 In Vitro & In Vivo Diagnostic Substances